Licarin A as a Novel Drug for Inflammatory Eye Diseases.

This study investigated the safety and therapeutic efficacy of licarin A (LCA) in the treatment of intraocular inflammation. safety of LCA in retinal pigmented epithelial cells (ARPE-19) and human embryonic stem cell derived-retinal pigmented epithelial cells (hES-RPE) was evaluated using CellTiter-Blue kit. The chorioallantoic membrane (CAM) assay was used to investigate LCA safety and antiangiogenic activity. safety of intravitreal LCA was accomplished by clinical examination (including assessment of intraocular pressure), electroretinography (ERG), and histopathology. Uveitis was induced in rats by subcutaneous and intravitreal injection of (BCG) antigen of . Intraocular inflammation was graded by slit-lamp and fundus examination, ERG, and histopathology. LCA was safe to cells and to the CAM at concentration below 12.0 μM. LCA significantly reduced the percentage of blood vessels in the CAM. Retinal safety and anti-inflammatory efficacy of intravitreal injection of LCA 6.0 μM were confirmed through clinical, functional, and histopathological evaluation. Significant reduction of inflammatory cytokines (tumor necrosis factor-α and interleukin-6) was also found, when compared to untreated animals. The results suggest that LCA is a potential new drug for the treatment of inflammatory eye disease.